Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN trial: optimal anticoagulation after catheter ablation for atrial fibrillation
2024-518736-37-00Phase 4Completed
- Sponsor
- University of Ottawa Heart Institute
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised trial in Atrial fibrillation (AFib) and stroke comparing Rivaroxaban arm with Aspirin arm (2 arms). Primary endpoint: Composite of stroke, systemic embolism, and covert embolic stroke. Started Nov 2024; status: completed.
02
Drugs
rivaroxabanaspirin
03
Conditions
Atrial fibrillation (AFib)stroke
Beyond the preview
Go deeper on 2024-518736-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518736-37-00.